ABCC7 p.Arg766Met

[switch to full view]
Comments [show]
Publications
PMID: 10878476 [PubMed] Ravnik-Glavac M et al: "Two novel missense mutations (R766M and R792G) in exon 13 of the CFTR gene in a patient with congenital bilateral absence of the vas deferens."
No. Sentence Comment
2 One is a substitution of thymine for guanine at nucleotide position 2429, which causes at amino acid level a substitution of methionine (R766M) for arginine at 766.
X
ABCC7 p.Arg766Met 10878476:2:137
status: NEW
Login to comment

21 No normal single-stranded DNAs (alleles) have been detected in sample 3 carrying mutations R766M and R792G.
X
ABCC7 p.Arg766Met 10878476:21:91
status: NEW
Login to comment

24 It is very likely that the newly detected genotype R766M/R792G in a CBAVD patient is connected with a disease phenotype.
X
ABCC7 p.Arg766Met 10878476:24:51
status: NEW
Login to comment

29 Frequency Both R766M and R792G have each been detected once in 84 CBAVD chromosomes and have not been found in 230 normal chromosomes tested in this study.
X
ABCC7 p.Arg766Met 10878476:29:15
status: NEW
Login to comment

30 Other Comments Single-strand conformational polymorphism (SSCP) analysis showed that R766M and R792G are present on different CFTR alleles of a CBAVD patient.
X
ABCC7 p.Arg766Met 10878476:30:85
status: NEW
Login to comment

PMID: 17660831 [PubMed] Baker JM et al: "CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices."
No. Sentence Comment
149 Milder phenotypes are seen for many cystic fibrosis-causing CFTR missense mutations within the R region, consistent with this multisite behavior, and the majority of these mutations are at the PKA recognition and phosphorylation sites (R709N, S712C, R735K, S737F, V754M, R766M, R810G and S813P; http://www.
X
ABCC7 p.Arg766Met 17660831:149:271
status: NEW
Login to comment

PMID: 20059485 [PubMed] Dorfman R et al: "Do common in silico tools predict the clinical consequences of amino-acid substitutions in the CFTR gene?"
No. Sentence Comment
64 Mutations in the CFTR gene grouped by clinical category Cystic fibrosis CFTR-related disease No disease T338I D614G L320V V920L L90S M470V H199R S1251N I203M G550R P111A I148T Q1291H R560K L1388Q L183I R170H I1027T S549R D443Y P499A L1414S T908N R668C S549N A455E E1401K Q151K G27E I1234L Y563N R347P C866R S1118C P1290S R75Q A559T V520F P841R M469V E1401G P67L G85E S50Y E1409K R933G G458V G178R Y1032C R248T I980K G85V V392G L973P L137H T351S R334W I444S V938G R792G R560T R555G L1339F D1305E P574H V1240G T1053I D58G G551D L1335P I918M F994C S945L L558S F1337V R810G D1152H G1247R P574S R766M D579G W1098R H949R F200I R352Q L1077P K1351E M244K L206W M1101K D1154G L375F N1303K R1066C E528D D110Y R347H R1070Q A800G P1021S S549K A1364V V392A damaging` (is supposed to affect protein function or structure) and 'probably damaging` (high confidence of affecting protein function or structure).
X
ABCC7 p.Arg766Met 20059485:64:590
status: NEW
Login to comment

PMID: 9736778 [PubMed] Vankeerberghen A et al: "Characterization of 19 disease-associated missense mutations in the regulatory domain of the cystic fibrosis transmembrane conductance regulator."
No. Sentence Comment
42 Of the 21 RD missense mutations, three (K698R, R766M and R792G) were located in PKA recognition consensus sites.
X
ABCC7 p.Arg766Met 9736778:42:47
status: NEW
Login to comment

43 Only R766M and R792G disrupted a PKA recognition site and might therefore interfere with CFTR regulation.
X
ABCC7 p.Arg766Met 9736778:43:5
status: NEW
Login to comment

68 Primers used for mutagenesis Primer Sequence I601F (a1933t) 5'-CTA ACA AAA CTA GGT TTT TGG TCA CTT C-3' L610S (t1961c) 5'-CTA AAA TGG AAC ATT CAA AGA AAG CTG-3' A613T (g1969a) 5'-CAT TTA AAG AAA ACT GAC AAA ATA TTA-3' D614G (a1973g) 5'-CAT TTA AAG AAA GCT GGC AAA ATA TTA A-3' I618T (t1985c) 5'-GAC AAA ATA TTA ACT TTG CAT GAA GG-3' L619S (t1988c) 5'-GAC AAA ATA TTA ATT TCG CAT GAA GGT-3' H620P (a1991c) 5'-CAA AAT ATT AAT TTT GCC TGA AGG TAG C-3' H620Q (t1992g) 5'-AAT ATT AAT TTT GCA GGA AGG TAG CAG-3' G622D (g1997a) 5'-TTG CAT GAA GAT AGC AGC TAT TTT TAT G-3' G628R (g2014c) 5'-GCA GCT ATT TTT ATC GGA CAT TTT C-3' L633P (t2030c) 5'-CAT TTT CAG AAC CCC AAA ATC TAC AGC-3' D648V (a2075t) 5'-CTC ATG GGA TGT GTT TCT TTC GAC C-3' T665S (a2125t) 5'-CAA TCC TAA CTG AGT CCT TAC ACC G-3' F693L (t2209c) 5'-CAG ACT GGA GAG CTT GGG GAA AAA AG-3' R766M (g2429t) 5'-GCA CGA AGG ATG CAG TCT GTC CTG-3' R792G (c2506g) 5'-CAG CAT CCA CAG GAA AAG TGT CAC TG-3' A800G (c2531g) 5'-CTG GCC CCT CAG GGA AAC TTG ACT G-3' I807M (a2553g) 5'-CTG AAC TGG ATA TGT ATT CAA GAA GG-3' E822K (g2596a) 5'-GGC TTG GAA ATA AGT AAA GAA ATT AAC G-3' E826K (g2608a) 5'-GAA GAA ATT AAC AAA GAA GAC TTA AAG-3' Selection primer BstBI 5'-CTC TGG GGT CCG GAA TGA CCG AC-3' Two primers were used for each mutagenesis reaction.
X
ABCC7 p.Arg766Met 9736778:68:843
status: NEW
Login to comment

77 Mutations detected in patients (I601F, L610S, A613T, D614G, I618T, L619S, H620P, H620Q, D622G, G628R, L633P, T665S, F693L, K698R, V754M, R766M, R792G, A800G, I807M, E822K and E826K) are indicated in bold and underlined, the PKA phosphorylation sites by an arrow and the two acidic domains are boxed.
X
ABCC7 p.Arg766Met 9736778:77:137
status: NEW
Login to comment

85 The remainder (G622D, D648V, F693L, R766M and I807M) did not significantly affect chloride transport ability when compared with wild-type CFTR channels.
X
ABCC7 p.Arg766Met 9736778:85:36
status: NEW
Login to comment

87 Maturation pattern of RD mutations and their associated phenotype found in patients with the indicated genotype (when the mutation is associated with CF, only the pancreas status is given) Mutation A-form B-form C-form Clinical data Genotype Phenotype Reference I601F + + - I601F/G542X PS M. Schwarz, personal communication L610S + + - Unknown Unknown A613T + + - Unknown Unknown D614G + + - D614G/unknown PI 14 I618T + + - I618T/dF508 PS G.R. Cutting, personal communication L619S + + - L619S/unknown PI B. Tümmler, personal communication H620P + + - H620P/R1158X PS M. Schwarz, personal communication H620Q + + + H620Q/dF508 PI T. Dörk, personal communication G622D + + + G622D/unknown Oligospermia J. Zielenski, personal communication G628R + + - Unknown Unknown L633P + + - L633P/3659delC M. Schwarz, personal communication D648V + + + D648V/3849+10kb C/T PI C. Ferec, personal communication T665S + + + Unknown Unknown F693L + + + F693L/W1282X Healthy C. Ferec; CF Genetic Analysis Consortium R766M + + + R766M/R792G CBAVD D. Glavac, personal communication R792G + + + R766M/R792G CBAVD D. Glavac, personal communication A800G + + + A800G/unknown CBAVD 34 I807M + + + I807M/unknown CBAVD Our observation E822K + + + E822K/unknown PI 35 E826K + + + E826K/unknown Thoracic sarcoidosis C. Bombieri, personal communication +, the protein matures up to that form; -, the protein does not reach the respective maturation step.
X
ABCC7 p.Arg766Met 9736778:87:1008
status: NEW
X
ABCC7 p.Arg766Met 9736778:87:1020
status: NEW
X
ABCC7 p.Arg766Met 9736778:87:1084
status: NEW
Login to comment

123 Mutations that did not affect maturation (H620Q, G622D, D648V, T665S, F693L, R766M, R792G, A800G, I807M, E822K and E826K) were subsequently analysedat theelectrophysiologi- cal level.
X
ABCC7 p.Arg766Met 9736778:123:77
status: NEW
Login to comment

131 The remaining mutations (D648V, T665S, F693L, R766M, I807M and E826K) caused no significant alterations in intrinsic chloride channel activity.
X
ABCC7 p.Arg766Met 9736778:131:46
status: NEW
Login to comment

PMID: 23060444 [PubMed] Wang G et al: "Regulation of Activation and Processing of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) by a Complex Electrostatic Interaction between the Regulatory Domain and Cytoplasmic Loop 3."
No. Sentence Comment
117 Because R764X and R766M were reported with CF patients (www.genet.sickkids.on.ca/cftr/app), we investigated if missense alanine mutation of R764 and R766 alters the channel processing and activity.
X
ABCC7 p.Arg766Met 23060444:117:18
status: NEW
Login to comment

141 However, the putative electrostatic attraction between K946/H950R and D835/D836/E838 failed to exert this inhibitory effect (Fig.4-5).
X
ABCC7 p.Arg766Met 23060444:141:18
status: NEW
Login to comment

PMID: 9175873 [PubMed] Annereau JP et al: "A novel model for the first nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator."
No. Sentence Comment
70 The maturation patterns of six mutant R domain proteins were determined (Fig. 3): CFTR-L610S, CFTR-G628R and CFTR-L633P matured to the core-glycosylated form, while CFTR-D648V, CFTR-T665S and CFTR-R766M matured to the complete glycosylated form.
X
ABCC7 p.Arg766Met 9175873:70:197
status: NEW
Login to comment

134 COS cells transfected with wild-type CFTR-L610S and CFTR-R766M were metabolically labelled, chased and CFTR was immunoprecipitated and separated on a SDS-PAGE gel.
X
ABCC7 p.Arg766Met 9175873:134:57
status: NEW
Login to comment

150 The mutations L610S (tc at 1961), G628R (gc at 2014), L633P (tc at 2030), D648V (at at 2075), T665S (at at 2125) and R766M (gt at 2429) (nucleotide and amino acid assignment according to [2]) were introduced using the Transformer Site-Directed Mutagenesis kit (Clontech, Heidelberg, Germany).
X
ABCC7 p.Arg766Met 9175873:150:117
status: NEW
Login to comment

135 COS cells transfected with wild-type CFTR-L610S and CFTR-R766M were metabolically labelled, chased and CFTR was immunoprecipitated and separated on a SDS-PAGE gel.
X
ABCC7 p.Arg766Met 9175873:135:57
status: NEW
Login to comment

151 The mutations L610S (tc at 1961), G628R (gc at 2014), L633P (tc at 2030), D648V (at at 2075), T665S (at at 2125) and R766M (gt at 2429) (nucleotide and amino acid assignment according to [2]) were introduced using the Transformer Site-Directed Mutagenesis kit (Clontech, Heidelberg, Germany).
X
ABCC7 p.Arg766Met 9175873:151:117
status: NEW
Login to comment

PMID: 11001817 [PubMed] Chen JM et al: "Definition of a "functional R domain" of the cystic fibrosis transmembrane conductance regulator."
No. Sentence Comment
62 The fact that R766M changes a most favorable phosphorylation sequence (R-R/K-X-S) to a less favorable one (R-X-X-S) suggests that even if R766M produces any effect, its effect must be minor and, in this regard, R766M did not show significant functional difference compared with wild-type CFTR (8).
X
ABCC7 p.Arg766Met 11001817:62:14
status: NEW
X
ABCC7 p.Arg766Met 11001817:62:138
status: NEW
X
ABCC7 p.Arg766Met 11001817:62:211
status: NEW
Login to comment